The field of hepatitis C disease management is in the midst of dramatic change. This series provides overviews, research updates, and more.

thumbnail image for headlineWhat Are the Hepatitis C Genotypes?

thumbnail image for headlineReal-World Hepatitis C Cure Rates Higher With 2 Direct Acting Agents

thumbnail image for headlineHepatitis C Resources, Services and Information

thumbnail image for headlineHCV Medications by Drug Class


HIV Viral Load Testing Capacities Progress, Require Global Support, Multiple Partners to Reach 90-90-90 Goals

Fixed-Dose Sofosbuvir/Velpatasvir/Voxilaprevir Cures 97% of Treatment-Experienced Hepatitis C Patients

This Week in HIV Research: Reducing Cardiovascular Risk; and Monitoring Renal Function With PrEP

Low Uptake of Direct-Acting Antivirals for Hepatitis C in U.S. Clinics -- Race and Income Key Factors

NIH's Dr. Dieffenbach Discusses Launch of HIV Vaccine Clinical Trial in South Africa

High Hepatitis C Cure Rates With Harvoni and Viekira Pak in Veterans With Genotype 1

Curing Hepatitis C Lowers but Does Not Eliminate Risk of Liver Cancer

Treatment With ABT-493/ABT-530 Cures 99% of Patients With Hepatitis C Genotype 2

MK3, a One-Pill Triple Direct-Acting Antiviral, Effective for Hepatitis C Genotypes 1, 2, and 3

Coordinated Care in Poor Neighborhoods Overcomes Some Barriers to Hepatitis C Treatment

Only 49% Transmission Rate Observed in Kidney Transplants From HCV-Positive Donors, but Lower Graft and Survival Overall

Hepatitis C Cure Rates Similar Among Specialists, Primary Care Providers, Nurses

Hepatitis C Cure Rate 93% With Elbasvir/Grazoprevir for Genotype 1 or 4

Top 10 HIV Clinical Developments of 2016

Use of Syringe Services Programs Increases, but Access Must Improve for Greater HIV Prevention